Analyst Price Targets — TVTX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| September 24, 2026 10:11 am | Vamil Divan | Guggenheim | $89.00 | $59.83 | StreetInsider | Travere Therapeutics (TVTX) PT Raised to $89 at Guggenheim |
| August 10, 2026 12:16 pm | — | Evercore ISI | $78.00 | $61.74 | TheFly | Travere Therapeutics price target raised to $78 from $68 at Evercore ISI |
| August 6, 2026 11:06 am | — | Canaccord Genuity | $70.00 | $62.76 | TheFly | Travere Therapeutics price target raised to $70 from $62 at Canaccord |
| June 25, 2026 11:38 am | Vamil Divan | Guggenheim | $65.00 | $59.40 | StreetInsider | Travere Therapeutics (TVTX) PT Raised to $65 at Guggenheim |
| June 2, 2026 3:38 pm | Joseph Pantginis | H.C. Wainwright | $67.00 | $42.96 | StreetInsider | Travere Therapeutics (TVTX) PT Raised to $67 at H.C. Wainwright |
| April 14, 2026 3:15 pm | — | Piper Sandler | $49.00 | $41.11 | TheFly | Travere Therapeutics upgraded to Overweight from Neutral at Piper Sandler |
| April 14, 2026 11:34 am | — | Guggenheim | $54.00 | $30.70 | TheFly | Travere Therapeutics price target raised to $54 from $49 at Guggenheim |
| January 14, 2026 11:48 am | Vamil Divan | Guggenheim | $49.00 | $28.39 | StreetInsider | Guggenheim Reiterates Buy rating and Best Idea on Travere Therapeutics (TVTX) |
| September 10, 2025 2:48 pm | Maury Raycroft | Jefferies | $35.00 | $27.31 | TheFly | AdCom cancellation 'clear positive' for Travere Therapeutics, says Jefferies |
| October 31, 2024 8:21 pm | Liisa Bayko | Evercore ISI | $33.00 | $17.50 | StreetInsider | Travere Therapeutics (TVTX) PT Raised to $33 at Evercore ISI |
Latest News for TVTX
SAN DIEGO--(BUSINESS WIRE)---- $TVTX--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that on October 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 178,580 shares of its common stock to 33 new employees, consisting of inducement stock options to purchase an aggregate of 36,000 shares of common stock and inducement restricted stock…
SAN DIEGO--(BUSINESS WIRE)---- $TVTX--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that it will share nine new data presentations, including five oral presentations, at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, CO, October 21-25. The presentations highlight compelling new data on FILSPARI® (sparsentan) in patients with IgA nephropathy (IgAN) and focal segmental…
NEW YORK, Sept. 30, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Travere Therapeutics, Inc. (NASDAQ: TVTX) breached their fiduciary duties to shareholders.
Travere Therapeutics, Inc. (NASDAQ: TVTX - Get Free Report)'s stock price gapped down before the market opened on Tuesday. The stock had previously closed at $62.86, but opened at $60.37. Travere Therapeutics shares last traded at $61.2310, with a volume of 306,408 shares trading hands. Analyst Upgrades and Downgrades Several brokerages have recently issued reports
Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for U.S. Paten
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for TVTX.
U.S. House Trading
No House trades found for TVTX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.